Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

Tineke E. Buffart, Kris G. Samsom, Linda J. W. Bosch, Luuk J. Schipper, Daoin Schout, Paul Roepman, Mirjam C. Boelens, Ferry Lalezari, Elisabeth G. Klompenhouwer, Adrianus J. de Langen, Berit M. H. van Linder, Kelly van Deventer, Kay van den Burg, Unga Unmehopa, Efraim H. Rosenberg, Roelof Koster, Frans B. L. Hogervorst, José G. van den Berg, Immy Riethorst, Lieke Schoenmaker, Daphne van Beek, Ewart de Bruijn, Jacobus J. M. van der Hoeven, Hans van Snellenberg, Lizet E. van der Kolk, Edwin Cuppen, Emile E. Voest, Gerrit A. Meijer, Kim Monkhorst

Published: 2023-12-13 DOI: 10.1038/s41596-023-00933-5

References

Introduction
Materials
Procedure
Troubleshooting
Timing
Anticipated results
Acknowledgements

Steeghs, E. M. P. et al. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer 167, 87–97 (2022).
Pasmans, C. T. B. et al. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev. Pharmacoecon. Outcomes Res. 21, 413–414 (2021).
Lynch, J. A. et al. Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010–2013. BMC Cancer 18, 306 (2018).
Samsom, K. G. et al. Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice. J. Pathol. 258, 179–188 (2022).
Brittain, H. K., Scott, R. & Thomas, E. The rise of the genome and personalised medicine. Clin. Med. 17, 545––551 (2017).
Nakagawa, H. & Fujita, M. Whole-genome sequencing analysis for cancer genomics and precision medicine. Cancer Sci. 109, 513–522 (2018).
van der Velden, D. L. et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127–131 (2019).
Schipper, L. J. et al. Clinical impact of prospective whole genome sequencing in sarcoma patients. Cancers (Basel) 14, http://doi.org/10.3390/cancers14020436 (2022).
Schipper, L. J. et al. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open http://doi.org/10.1016/j.esmoop.2022.100611 (2022).
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Zhang, J. et al. The international cancer genome consortium data portal. Nat. Biotechnol. 37, 367–369 (2019).
Marshall, C. R. et al. The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Med. 12, 48 (2020).
van de Ven, M. et al. Whole-genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer 21, 488 (2021).
Kawanishi, M., Matsuda, T. & Yagi, T. Genotoxicity of formaldehyde: molecular basis of DNA damage and mutation. Front. Environ. Sci. http://doi.org/10.3389/fenvs.2014.00036 (2014).
Bass, B. P., Engel, K. B., Greytak, S. R. & Moore, H. M. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen. Arch. Pathol. Lab. Med. 138, 1520–1530 (2014).
Robbe, P. et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. Genet. Med. 20, 1196–1205 (2018).
Turnbull, C. Introducing whole-genome sequencing into routine cancer care: the Genomics England 100,000 Genomes Project. Ann. Oncol. 29, 784–787 (2018).
Meggendorfer, M. et al. Analytical demands to use whole-genome sequencing in precision oncology. Semin. Cancer Biol. 84, 16–22 (2022).
Roepman, P. et al. Clinical validation of whole genome sequencing for cancer diagnostics. J. Mol. Diagn. 23, 816–833 (2021).
Mandelker, D. et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann. Oncol. 30, 1221–1231 (2019).
VKGN. 20211006 Adviezen projectgroep tumor—en erfelijkheidsdiagnostiek definitief. http://www.artsengenetica.nl/sites/default/files/inline-files/tabel-3-versie-mei-2023.pdf (2021).
Nguyen, L., Van Hoeck, A. & Cuppen, E. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Nat. Commun. 13, 4013 (2022).
Martínez-Jiménez, F. et al. Genetic immune escape landscape in primary and metastatic cancer. Nat. Genet. 55, 820–831 (2023).
Zhao, C. et al. TruSight Oncology 500: enabling comprehensive genomic profiling and biomarker reporting with targeted sequencing. Preprint at bioRxiv http://doi.org/10.1101/2020.10.21.349100 (2020).
Cheng, D. T. et al. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251–264 (2015).
Vestergaard, L. K., Oliveira, D. N. P., Poulsen, T. S., Hogdall, C. K. & Hogdall, E. V. Oncomine comprehensive assay v3 vs. Oncomine comprehensive assay plus. Cancers http://doi.org/10.3390/cancers13205230 (2021).
Hesselink, A. T. et al. Clinical validation of Anyplex II HPV HR detection according to the guidelines for HPV test requirements for cervical cancer screening. J. Clin. Virol. 76, 36–39 (2016).
Willems, A. J. et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin. Cancer Res. 14, 2953–2961 (2008).
van Wijk, L. M., Nilas, A. B., Vrieling, H. & Vreeswijk, M. P. G. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? Expert Rev. Mol. Diagn. 22, 185–199 (2022).
Schouten, P. C. et al. Ovarian cancer-specific BRCA-like copy-number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial. Clin. Cancer Res. 27, 6559–6569 (2021).
Szilagyi, M. et al. Circulating cell-free nucleic acids: main characteristics and clinical application. Int. J. Mol. Sci. http://doi.org/10.3390/ijms21186827 (2020).
Wrzeszczynski, K. O. et al. Analytical validation of clinical whole-genome and transcriptome sequencing of patient-derived tumors for reporting targetable variants in cancer. J. Mol. Diagn. 20, 822–835 (2018).
Nelson, A. C. & Yohe, S. L. Cancer whole-genome sequencing: the quest for comprehensive genomic profiling in routine oncology care. J. Mol. Diagn. 23, 784–787 (2021).
Cuppen, E. et al. Implementation of whole-genome and transcriptome sequencing into clinical cancer care. JCO Precis. Oncol. 6, e2200245 (2022).
Hu, B., Sajid, M., Lv, R., Liu, L. & Sun, C. A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology. Front. Immunol. 13, 996721 (2022).
Laroche, F. J. F. et al. S1P1 Threonine 236 phosphorylation mediates the invasiveness of triple-negative breast cancer and sensitivity to FTY720. Cells http://doi.org/10.3390/cells12070980 (2023).
Hernandez, S. et al. Differential spatial gene and protein expression associated with recurrence following chemoradiation for localized anal squamous cell cancer. Cancers http://doi.org/10.3390/cancers15061701 (2023).
Friedrich, C. et al. Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories. Nat. Commun. 12, 3576 (2021).
Norton, S. E., Lechner, J. M., Williams, T. & Fernando, M. R. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin. Biochem. 46, 1561–1565 (2013).
Orchard, G. E. et al. New embedding and staining systems PrestoCHILL and Presto stainer for application in the advancement of Mohs micrographic surgery. Br. J. Biomed. Sci. 74, 203–208 (2017).
Samsom, K. G. et al. Study protocol: whole-genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE). BMC Med. Genomics 13, 169 (2020).
Veneroni, S. et al. Applicability of under vacuum fresh tissue sealing and cooling to omics analysis of tumor tissues. Biopreserv. Biobank 14, 480–490 (2016).
Piaton, E. et al. Guidelines for May-Grunwald-Giemsa staining in haematology and non-gynaecological cytopathology: recommendations of the French Society of Clinical Cytology (SFCC) and of the French Association for Quality Assurance in Anatomic and Cytologic Pathology (AFAQAP). Cytopathology 27, 359–368 (2016).
Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210–216 (2019).
Kohsaka, S., Petronczki, M., Solca, F. & Maemondo, M. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. Future Oncol. 15, 637–652 (2019).
Casparie, M. et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 29, 19–24 (2007).

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice

Supplementary information

Supplementary Information

推荐阅读